Orthopedic Applications of Platelet-Rich Plasma
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage determinations for use of platelet-rich plasma in orthopedic indications for Blue Cross Blue Shield - Rhode Island members, addressing both Medicare Advantage and commercial products.
No material clinical or coverage changes in this revision.
Coverage Determinations
General coverage determination
Covered when ALL of the following are met:
Applies across tendinopathies, non-tendon soft tissue injuries, osteochondral lesions, knee/hip osteoarthritis, and adjunct-to-surgery indications summarized in the policy.
Adjunct to Orthopedic Surgery — subacromial decompression and total knee arthroplasty
Evidence summary and resulting coverage implication for use of PRP as an adjunct to orthopedic surgery:
Evidence insufficient — benefit not established
Evidence insufficient — benefit not established
Providers should refer to coding section for specific non-covered procedure and supply codes.
For Medicare Advantage members, use of platelet-rich plasma (PRP) for all orthopedic indications is not covered because the evidence is insufficient to demonstrate an improvement in net health outcome. For Commercial products, PRP for all orthopedic indications is considered not medically necessary for the same reason — available studies do not establish a clear clinical benefit.
The following procedure and supply codes are explicitly not covered for Medicare Advantage Plans and are not medically necessary for Commercial products: 0481T, 0232T, C1734, and P9020. These codes correspond to PRP/autologous protein solution injections, an orthopedic implantable matrix, and PRP units as listed in the coding section.
For Commercial products the policy specifies that use of platelet-rich plasma for all orthopedic indications is not medically necessary. In practice, billing or claims that include the identified codes (0232T, 0481T, C1734, P9020) are subject to denial because the services are designated as not medically necessary under this policy.
Use of PRP as an adjunct to orthopedic surgery (for example, with subacromial decompression or total knee arthroplasty) does not have sufficient high-quality evidence to demonstrate a net health benefit. A single small randomized trial of PRP with subacromial decompression showed some subjective pain and range-of-motion improvements but no reduction in certain stability scores, and systematic reviews for PRP with total knee arthroplasty found no significant differences in range of motion, function, or long-term pain. Overall, the evidence is insufficient to support clinical benefit when PRP is used as a surgical adjunct.
Billing and Coding
| 0481T | Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed |
| 0232T | Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed |
| C1734 | Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable) |
| P9020 | Platelet rich plasma, each unit |
| 0481T | Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed |
| 0232T | Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed |
| C1734 | Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable) |
| P9020 | Platelet rich plasma, each unit |
Provider Requirements and Actions
Prior Authorization and Benefit Verification
Prior authorization is not applicable for this policy. Providers must verify member benefits and eligibility prior to rendering services.
- Prior authorization: Not applicable
- Verify member-specific benefits and eligibility with the provider call center before services are rendered
- Refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable benefits and coverage determinations
Coverage and Prior Authorization Note
Providers should confirm coverage and prior authorization requirements with BCBSRI before providing services. This policy states that platelet-rich plasma (PRP) for orthopedic indications is either not covered or not medically necessary depending on product type.
- Benefits may vary by group/contract; confirm member-specific coverage
- Medicare Advantage: PRP for all orthopedic indications is not covered
- Commercial products: PRP for all orthopedic indications is considered not medically necessary
Coverage Denial Risk for PRP
Use of platelet-rich plasma (PRP) for orthopedic indications carries a high risk of coverage denial — it is not covered for Medicare Advantage and is not medically necessary for Commercial products.
- Coverage denial risk: PRP for orthopedic indications
Not Covered Codes Trigger Denial
The following codes are not covered for Medicare Advantage Plans and are considered not medically necessary for Commercial products; claims billed with these codes may be denied.
- 0481T — Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed
- 0232T — Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed
- C1734 — Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to-bone (implantable)
- P9020 — Platelet rich plasma, each unit
Background and Rationale
Platelet-rich plasma (PRP) is an autologous concentration of platelets suspended in plasma that contains growth factors thought to promote wound healing and tissue repair. PRP can be prepared by centrifugation of autologous blood and may be activated (for example, with thrombin or calcium chloride) to release growth factors and form a platelet gel. PRP is proposed for use either as an injectable therapy into tissues (eg, tendons, joints) or as a topical/operative adjunct applied during surgery.
Definitions and Regulatory Status
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.